title: How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.
authors.affiliation: Division of Kidney Diseases and Hypertension, Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Hofstra North Shore-LlJ School of Medicine, Great Neck, New York.
authors.forename: Hitesh H
authors.initials: HH
authors.lastname: Shah
authors.forename: Steven N
authors.initials: SN
authors.lastname: Fishbane
mesh_terms: D000728:Androgens / Q000627:therapeutic use; D000740:Anemia / Q000188:drug therapy*; D001205:Ascorbic Acid / Q000627:therapeutic use; D002331:Carnitine / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D000068256:Darbepoetin alfa; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000628:therapy*
chemical_list: D000728:Androgens; D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D001205:Ascorbic Acid; D002331:Carnitine